FGFR2+ cholangiocarcinoma: pemigatinib active as second-line treatment Presented ByProf. Antoine Hollebecque, Gustave Roussy Cancer Center, France TrialPhase 2, FIGHT-202 ConferenceESMO 2019 TypePeer-reviewed article 26 November 2019 18:21